• Explore /
  • Poster
  • / An international phase 3 randomized, placebo-controlled study of CC-486 (oral azacitidine) maintenance therapy in patients with acute myeloid leukemia (AML) in complete remission (CR): The Quazar AML maintenance trial.

An international phase 3 randomized, placebo-controlled study of CC-486 (oral azacitidine) maintenance therapy in patients with acute myeloid leukemia (AML) in complete remission (CR): The Quazar AML maintenance trial.

Abstract Poster

Authors

Gail Roboz

Gail J. Roboz

Weill Medical College of Cornell University and the New York Presbyterian Hospital, New York, NY

Gail J. Roboz , Farhad Ravandi , Dominik Selleslag , Pau Montesinos , Andrew Wei , Kimmo Porkka , Antonio Almeida , Michael R. Savona , Sanjay Ram Mohan , Jose F Falantes , Maria Teresa Voso , Keshava Kumar , Frederic Camus , Ignazia La Torre , Hagop Kantarjian , Barry Skikne

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Leukemia, Myelodysplasia, and Transplantation

Track

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Sub Track

Leukemia

Clinical Trial Registration Number

NCT01757535

Citation

J Clin Oncol 33, 2015 (suppl; abstr TPS7097)

DOI

10.1200/jco.2015.33.15_suppl.tps7097

Abstract #

TPS7097

Poster Bd #

84b

Abstract Disclosures

Similar Posters

First Author: Farhad Ravandi

First Author: Somayeh Sadat Shariatmaghani

First Author: Gail J. Roboz

First Author: Amer Methqal Zeidan